Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for protease activated receptor 4
Most Correlated Studies
- L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
- L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
- L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
- L1000 CMAP - Amelanotic malignant melanoma of skin A375 cells treated with ligand perturbagens
- L1000 CMAP - Adenocarcinoma of breast MCF7 cells treated with ligand perturbagens
Most Relevant Literature
- Lumbosacral spinal proteomic changes during PAR4-induced persistent bladder pain.
- MicroRNA-26a alleviates tubulointerstitial fibrosis in diabetic kidney disease by targeting PAR4.
- Role of protease-activated receptor 4 in mouse models of acute and chronic kidney injury.
- Discovery of Potent and Selective Quinoxaline-Based Protease-Activated Receptor 4 (PAR4) Antagonists…
- Inhibitors of protease-activated receptor 4 (PAR4): a review of recent patents (2013-2021).
Most Relevant Clinical Trials
- Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the C…
- Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase Inhibito…
- Efficacy of Aerosol Combination Therapy of 13 Cis Retinoic Acid and Captopril for Treating Covid-19 …
- Bradykinin Receptor Antagonism During Cardiopulmonary Bypass
- Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 …
